David Liu Profile picture
Medical Oncologist. Computational Biologist. Former software engineer. Stanford Economics BA '99 | Computer Science MS '01 | Hopkins MPH '10 | MD '11
Dec 5, 2019 20 tweets 26 min read
A thread on our recent analysis of WES, RNAseq, and clinical predictors of response to PD-1 ICB in metastatic melanoma patients led by @vanallenlab, Dirk Schadendorf, and Bastian Schilling with many others!
@NatureMedicine @DanaFarber @broadinstitute
nature.com/articles/s4159… @VanAllenLab @NatureMedicine @DanaFarber @broadinstitute Our cohort was 144 metastatic melanoma patients who received PD-1 ICB. Overall response rate (CR or PR) was 38%; and subtypes were 86% cutaneous or occult melanoma, 7% acral, and 7% mucosal. Median follow-up was 30 months. 39% had BRAF mutations, 30% NRAS, and 17% NF1. [2/n]